DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/9jsxk2/keratoconjunctivit) has announced the addition of the “Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2015” report to their offering. This repo…
Eleven Biotherapeutics reported a net loss of $9.7 million, or $0.50 per share, in the third quarter compared with a net loss of $10.7 million, or $0.66 per share, in the same quarter of 2014, according to a press release. Revenue was reported at $0.1 …
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/n7kfbw/global) has announced the addition of the “Global Ophthalmology Devices – Industry Analysis 2015-2019” report to their offering. The global ophthalmology d…
NEW YORK — At OSN New York 2015, Parag A. Majmudar, MD, discusses the early U.S. experience with the AcuFocus’ Kamra inlay. The Kamra inlay does show some promise in allowing us to improve patients’ near vision while maintaining distance vision with minimal loss of quality.
LAS VEGAS–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in several presentations and courses at the annual American Academy of Ophthalmology (AAO) meeting being held in Las Vegas, Nevada on November 14 – 17, 2015. In addition, Glaukos will host a major symposium
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international study, published in the November 2015 issue of Clinical Ophthalmology, showed that two iStent® Trabecular Micro-Bypass Stents provided “statistically significant, sustained and safe reduction in intraocular